Effects of imidazoline-like drugs on liver and adipose tissues, and their role in preventing obesity and associated cardio-metabolic disorders.

Background/objectives: We previously observed that selective agonists of the sympatho-inhibitory I imidazoline receptors (LNP ligands) have favorable effects on several cardiovascular and metabolic disorders defining the metabolic syndrome, including body weight. The objectives of this study were to explore the effects of LNPs on adiposity and the mechanisms involved, and to evaluate their impact on metabolic homeostasis.

Methods: Young Zucker fa/fa rats were treated with LNP599 (10 mg/kg/day) for 12 weeks.